

**Bellerophon Therapeutics, Inc.**  
**184 Liberty Corner Road, Suite 302**  
**Warren, New Jersey 07059**

July 3, 2018

**Via EDGAR**

Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Mail Stop 3561  
Washington, D.C. 20549  
Attention: Abigail Hayes  
Mary Beth Breslin

Re: **Bellerophon Therapeutics, Inc.**  
**Registration Statement on Form S-3**  
**Filed on June 25, 2018**  
**File No. 333-225878**

Dear Ms. Hayes:

Pursuant to Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, Bellerophon Therapeutics, Inc. (the "Company") hereby requests that the effectiveness of the above-captioned Registration Statement on Form S-3 be accelerated to Friday, July 6, 2018, at 9:00 a.m., Eastern Time, or as soon as thereafter practicable.

Any questions should be addressed to Jeffrey Schultz, Esq., at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Chrysler Center, 666 Third Avenue, New York, New York 10017, telephone (212) 692-6732.

Thank you very much.

Very truly yours,

Bellerophon Therapeutics, Inc.

/s/ Fabian Tenenbaum

---

By: Fabian Tenenbaum  
Title: Chief Executive Officer

cc: Abigail Jacobs, *Securities and Exchange Commission*  
Mary Beth Breslin, *Securities and Exchange Commission*  
Jeffrey Schultz, Esq., *Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.*